Researchers in Shanghai have developed a gene vaccine for the H7N9 bird flu virus for humans that has so far shown success in preliminary animal tests, officials under the Shanghai Public Health Clinical Center announced. This time it’s really going places, guys.
At least we hope.
In an experiment, none of the 30 lab nice who received the vaccine contracted the flu within 30 days of being inoculated and exposed to the H7N9 virus, Shanghai Television Station reported.
“European researchers have developed two inactivated H7 avian influenza vaccines, but clinical experiments have shown failure results,” Xu Jianqing, an official under the SPHCC, said in a CRIEnglish report. “We found a similar problem in our research. Having considered the risk of failure of using an inactivated H7 vaccine, we switched to the other solution, which is genetically engineering a vaccine.”
Researchers are now applying to launch clinical experiments for the vaccine and are further working to develop antibodies against the virus–the creation of which could lead to a cure for people already infected.
A study released in the Clinical Infections Diseases journal last weekend showed that a gene which increases the flu’s severity is significantly more common in people of Chinese ancestry.